<p>Reynders McVeigh Capital Management LLC 在第二季度購買了 Novo Nordisk A/S（紐約證券交易所代碼：NVO - 免費報告）的新股份，根據其最近向證券交易委員會的備案。該基金購買了 363,889 股公司股票，價值約為 25,116,000 美元。</p>
<p>獲取 <strong>Novo Nordisk A/S</strong> 警報：</p>
<ul>
<li>黃金交叉警報：3 只具有重大上漲潛力的股票</li>
</ul>
<p>其他機構投資者和對沖基金也調整了對該公司的持股。Revolve Wealth Partners LLC 在第四季度將其在 Novo Nordisk A/S 的持股增加了 8.7%。Revolve Wealth Partners LLC 目前擁有 2,490 股公司股票，價值 214,000 美元，此前在上個季度又購買了 200 股。Charles Schwab Investment Management Inc. 在第一季度將其在 Novo Nordisk A/S 的持股增加了 15.6%。Charles Schwab Investment Management Inc. 目前擁有 261,243 股公司股票，價值 18,141,000 美元，此前在該期間又收購了 35,329 股。Kovitz Investment Group Partners LLC 在第一季度將其在 Novo Nordisk A/S 的持股增加了 7.5%。Kovitz Investment Group Partners LLC 目前擁有 74,182 股公司股票，價值 5,151,000 美元，此前在上個季度又收購了 5,194 股。Horizon Investments LLC 在第一季度將其在 Novo Nordisk A/S 的持股增加了 117.4%。Horizon Investments LLC 目前擁有 5,466 股公司股票，價值 380,000 美元，此前在上個季度又購買了 2,952 股。最後，Aberdeen Group plc 在第一季度將其在 Novo Nordisk A/S 的持股增加了 7.9%。Aberdeen Group plc 目前擁有 280,734 股公司股票，價值 19,494,000 美元，此前在上個季度又購買了 20,565 股。目前，11.54% 的股票由機構投資者和對沖基金持有。</p>
<h2>分析師評級調整</h2>
<p>幾位分析師最近對 NVO 股票發表了看法。Zacks Research 在 12 月 3 日的研究報告中將 Novo Nordisk A/S 的評級從 “持有” 下調至 “強烈賣出”。Jefferies Financial Group 在 10 月 27 日的研究報告中開始覆蓋 Novo Nordisk A/S，並對該公司給予了 “表現不佳” 的評級。Sanford C. Bernstein 在 9 月 9 日的報告中將 Novo Nordisk A/S 的評級從 “市場表現” 上調至 “跑贏大盤”。TD Cowen 在 8 月 19 日的報告中將 Novo Nordisk A/S 的目標價從 105.00 美元下調至 70.00 美元，並對該股票給予了 “買入” 評級。最後，摩根士丹利在 11 月 28 日的報告中將 Novo Nordisk A/S 的目標價從 60.00 美元下調至 54.00 美元，並對該公司給予了 “買入” 評級。一位投資分析師對該股票給予了強烈買入評級，六位分析師給予了買入評級，十二位分析師給予了持有評級，三位分析師給予了賣出評級。根據 MarketBeat 的數據，該公司目前的平均評級為 “持有”，共識目標價為 53.33 美元。</p>
<ul>
<li>HIMS 的股價波動不定。投資者應該入場嗎？</li>
</ul>
<p><strong>獲取我們對 NVO 的最新分析</strong></p>
<h2>Novo Nordisk A/S 股票下跌 0.3%</h2>
<p>NVO 股票在週一開盤價為 50.12 美元。該公司的速動比率為 0.57，流動比率為 0.78，債務與股本比率為 0.52。該公司的市值為 2,237.9 億美元，市盈率為 14.57，貝塔值為 0.67。該股票的 50 日移動平均線為 50.86 美元，200 日移動平均線為 58.29 美元。Novo Nordisk A/S 的 12 個月低點為 43.08 美元，12 個月高點為 109.88 美元。</p>
<ul>
<li>年初至今下跌 45%，Novo Nordisk 引發價格戰</li>
</ul>
<p>Novo Nordisk A/S（紐約證券交易所代碼：NVO - 獲取免費報告）最近於 11 月 5 日發佈了季度財報。該公司報告每股收益為 1.02 美元，超出分析師共識預期的 0.77 美元，超出幅度為 0.25 美元。Novo Nordisk A/S 的淨利潤率為 32.76%，股本回報率為 73.50%。該公司季度收入為 117.9 億美元，而分析師預期為 119.8 億美元。賣方分析師預計 Novo Nordisk A/S 本財年將發佈 3.84 美元的每股收益。</p>
<h2>Novo Nordisk A/S 公司簡介</h2>
<p>（免費報告）</p>
<p>Novo Nordisk A/S 及其子公司從事藥品的研究與開發、製造和分銷業務，覆蓋歐洲、中東、非洲、中國大陸、香港、台灣、北美及國際市場。它分為兩個部門，分別是糖尿病與肥胖護理和罕見疾病。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Novo Nordisk A/S</li>
<li>S&amp;P/TSX 指數是什麼？</li>
<li>3 只被低估的機器人股票，準備迎來鉅額收益</li>
<li>2022-2025 年股市假期 - 紐約證券交易所和納斯達克將關閉的時間</li>
<li>Dave &amp; Buster’s 的反轉在雙底突破後進入實施階段</li>
<li>市盈率計算：如何評估股票</li>
<li>3 只在 10 年期國債收益率上升時值得購買的金融股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WTw"/></p>
<p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Novo Nordisk A/S 嗎？</h2>
<p>在考慮投資 Novo Nordisk A/S 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Novo Nordisk A/S 並不在名單上。</p>
<p>雖然 Novo Nordisk A/S 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票的詳細信息</p>

諾和諾德公司

<p>Reynders McVeigh Capital Management LLC 在第二季度收購了 363,889 股諾和諾德公司（Novo Nordisk A/S），價值 25,116,000 美元。機構投資者持有該股票的 11.54%。分析師的評級各不相同：一項 “強力買入”，六項 “買入”，十二項 “持有”，三項 “賣出”。該股票開盤價為 50.12 美元，市值為 2,237.9 億美元。諾和諾德公司報告第三季度每股收益為 1.02 美元，超出預期 0.25 美元，收入為 117.9 億美元</p>

<p>Reynders McVeigh Capital Management LLC bought a new position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) during the 2nd quarter, according to its most recent filing with the Securities &amp; Exchange Commission. The fund bought 363,889 shares of the company's stock, valued at approximately $25,116,000.</p>
<div class="lb-trans"><p>Reynders McVeigh Capital Management LLC 在第二季度購買了 Novo Nordisk A/S（紐約證券交易所代碼：NVO - 免費報告）的新股份，根據其最近向證券交易委員會的備案。該基金購買了 363,889 股公司股票，價值約為 25,116,000 美元。</p>
</div><p>Get <strong>Novo Nordisk A/S</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Novo Nordisk A/S</strong> 警報：</p>
</div><ul>
<li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>黃金交叉警報：3 只具有重大上漲潛力的股票</li>
</ul>
</div><p>Other institutional investors and hedge funds have also modified their holdings of the company. Revolve Wealth Partners LLC lifted its holdings in shares of Novo Nordisk A/S by 8.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock valued at $214,000 after purchasing an additional 200 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Novo Nordisk A/S by 15.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 261,243 shares of the company's stock valued at $18,141,000 after acquiring an additional 35,329 shares during the period. Kovitz Investment Group Partners LLC increased its stake in Novo Nordisk A/S by 7.5% in the first quarter. Kovitz Investment Group Partners LLC now owns 74,182 shares of the company's stock valued at $5,151,000 after acquiring an additional 5,194 shares during the last quarter. Horizon Investments LLC lifted its stake in Novo Nordisk A/S by 117.4% during the first quarter. Horizon Investments LLC now owns 5,466 shares of the company's stock worth $380,000 after purchasing an additional 2,952 shares during the last quarter. Finally, Aberdeen Group plc boosted its holdings in shares of Novo Nordisk A/S by 7.9% in the 1st quarter. Aberdeen Group plc now owns 280,734 shares of the company's stock valued at $19,494,000 after purchasing an additional 20,565 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他機構投資者和對沖基金也調整了對該公司的持股。Revolve Wealth Partners LLC 在第四季度將其在 Novo Nordisk A/S 的持股增加了 8.7%。Revolve Wealth Partners LLC 目前擁有 2,490 股公司股票，價值 214,000 美元，此前在上個季度又購買了 200 股。Charles Schwab Investment Management Inc. 在第一季度將其在 Novo Nordisk A/S 的持股增加了 15.6%。Charles Schwab Investment Management Inc. 目前擁有 261,243 股公司股票，價值 18,141,000 美元，此前在該期間又收購了 35,329 股。Kovitz Investment Group Partners LLC 在第一季度將其在 Novo Nordisk A/S 的持股增加了 7.5%。Kovitz Investment Group Partners LLC 目前擁有 74,182 股公司股票，價值 5,151,000 美元，此前在上個季度又收購了 5,194 股。Horizon Investments LLC 在第一季度將其在 Novo Nordisk A/S 的持股增加了 117.4%。Horizon Investments LLC 目前擁有 5,466 股公司股票，價值 380,000 美元，此前在上個季度又購買了 2,952 股。最後，Aberdeen Group plc 在第一季度將其在 Novo Nordisk A/S 的持股增加了 7.9%。Aberdeen Group plc 目前擁有 280,734 股公司股票，價值 19,494,000 美元，此前在上個季度又購買了 20,565 股。目前，11.54% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級調整</h2>
</div><p>Several analysts recently weighed in on NVO shares. Zacks Research downgraded Novo Nordisk A/S from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research report on Wednesday, December 3rd. Jefferies Financial Group initiated coverage on Novo Nordisk A/S in a research report on Monday, October 27th. They issued an &#34;underperform&#34; rating for the company. Sanford C. Bernstein upgraded Novo Nordisk A/S from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating in a report on Tuesday, September 9th. TD Cowen reduced their target price on shares of Novo Nordisk A/S from $105.00 to $70.00 and set a &#34;buy&#34; rating on the stock in a report on Tuesday, August 19th. Finally, The Goldman Sachs Group decreased their price objective on Novo Nordisk A/S from $60.00 to $54.00 and set a &#34;buy&#34; rating for the company in a report on Friday, November 28th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of &#34;Hold&#34; and a consensus price target of $53.33.</p>
<div class="lb-trans"><p>幾位分析師最近對 NVO 股票發表了看法。Zacks Research 在 12 月 3 日的研究報告中將 Novo Nordisk A/S 的評級從 “持有” 下調至 “強烈賣出”。Jefferies Financial Group 在 10 月 27 日的研究報告中開始覆蓋 Novo Nordisk A/S，並對該公司給予了 “表現不佳” 的評級。Sanford C. Bernstein 在 9 月 9 日的報告中將 Novo Nordisk A/S 的評級從 “市場表現” 上調至 “跑贏大盤”。TD Cowen 在 8 月 19 日的報告中將 Novo Nordisk A/S 的目標價從 105.00 美元下調至 70.00 美元，並對該股票給予了 “買入” 評級。最後，摩根士丹利在 11 月 28 日的報告中將 Novo Nordisk A/S 的目標價從 60.00 美元下調至 54.00 美元，並對該公司給予了 “買入” 評級。一位投資分析師對該股票給予了強烈買入評級，六位分析師給予了買入評級，十二位分析師給予了持有評級，三位分析師給予了賣出評級。根據 MarketBeat 的數據，該公司目前的平均評級為 “持有”，共識目標價為 53.33 美元。</p>
</div><ul>
<li>HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?</li>
</ul>
<div class="lb-trans"><ul>
<li>HIMS 的股價波動不定。投資者應該入場嗎？</li>
</ul>
</div><p><strong>Get Our Latest Analysis on NVO</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 NVO 的最新分析</strong></p>
</div><h2>Novo Nordisk A/S Stock Down 0.3%</h2>
<div class="lb-trans"><h2>Novo Nordisk A/S 股票下跌 0.3%</h2>
</div><p>NVO stock opened at $50.12 on Monday. The company has a quick ratio of 0.57, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $223.79 billion, a PE ratio of 14.57 and a beta of 0.67. The stock's 50 day moving average is $50.86 and its 200-day moving average is $58.29. Novo Nordisk A/S has a twelve month low of $43.08 and a twelve month high of $109.88.</p>
<div class="lb-trans"><p>NVO 股票在週一開盤價為 50.12 美元。該公司的速動比率為 0.57，流動比率為 0.78，債務與股本比率為 0.52。該公司的市值為 2,237.9 億美元，市盈率為 14.57，貝塔值為 0.67。該股票的 50 日移動平均線為 50.86 美元，200 日移動平均線為 58.29 美元。Novo Nordisk A/S 的 12 個月低點為 43.08 美元，12 個月高點為 109.88 美元。</p>
</div><ul>
<li>Down 45% Year-to-Date, Novo Nordisk Ignites a Price War</li>
</ul>
<div class="lb-trans"><ul>
<li>年初至今下跌 45%，Novo Nordisk 引發價格戰</li>
</ul>
</div><p>Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, beating analysts' consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. The company had revenue of $11.79 billion for the quarter, compared to analyst estimates of $11.98 billion. Sell-side analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Novo Nordisk A/S（紐約證券交易所代碼：NVO - 獲取免費報告）最近於 11 月 5 日發佈了季度財報。該公司報告每股收益為 1.02 美元，超出分析師共識預期的 0.77 美元，超出幅度為 0.25 美元。Novo Nordisk A/S 的淨利潤率為 32.76%，股本回報率為 73.50%。該公司季度收入為 117.9 億美元，而分析師預期為 119.8 億美元。賣方分析師預計 Novo Nordisk A/S 本財年將發佈 3.84 美元的每股收益。</p>
</div><h2>Novo Nordisk A/S Company Profile</h2>
<div class="lb-trans"><h2>Novo Nordisk A/S 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.</p>
<div class="lb-trans"><p>Novo Nordisk A/S 及其子公司從事藥品的研究與開發、製造和分銷業務，覆蓋歐洲、中東、非洲、中國大陸、香港、台灣、北美及國際市場。它分為兩個部門，分別是糖尿病與肥胖護理和罕見疾病。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Novo Nordisk A/S</li>
<li>What is the S&amp;P/TSX Index?</li>
<li>3 Underrated Robotics Stocks Poised for Huge Gains</li>
<li>Stock Market Holidays 2022-2025 - Here’s When the NYSE and NASDAQ Will be Closed</li>
<li>Dave &amp; Buster’s Reversal Is in PLAY After Double-Bottom Breakout</li>
<li>P/E Ratio Calculation: How to Assess Stocks</li>
<li>3 Finance Stocks to Buy on Rising 10-Year Treasury Rates</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Novo Nordisk A/S</li>
<li>S&amp;P/TSX 指數是什麼？</li>
<li>3 只被低估的機器人股票，準備迎來鉅額收益</li>
<li>2022-2025 年股市假期 - 紐約證券交易所和納斯達克將關閉的時間</li>
<li>Dave &amp; Buster’s 的反轉在雙底突破後進入實施階段</li>
<li>市盈率計算：如何評估股票</li>
<li>3 只在 10 年期國債收益率上升時值得購買的金融股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WTw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=NVO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Novo Nordisk A/S Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Novo Nordisk A/S 嗎？</h2>
</div><p>Before you consider Novo Nordisk A/S, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 Novo Nordisk A/S 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Novo Nordisk A/S 並不在名單上。</p>
</div><p>While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Novo Nordisk A/S 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票的詳細信息</p>
</div>

Reynders McVeigh Capital Management LLC 收購諾和諾德公司 $NVO 的新股